Project #68: Direct reprogramming pancreatic ductal cells into insulin-producing cells by controlling the epigenome using AI-designed mini-protein EpiBinder
This grant funds research using AI-designed EpiBinder proteins to reprogram pancreatic ductal cells into insulin-producing cells for innovative Type 1 Diabetes therapy.
Funder: Diabetes Research Connection
Due Dates: Rolling
Funding Amounts: Up to $75,000 per project; typically supports early-stage, innovative research on Type 1 Diabetes.
Summary: Supports research using AI-designed mini-proteins to reprogram pancreatic ductal cells into insulin-producing cells for Type 1 Diabetes therapy.
Key Information: Ideal for early-career scientists pursuing novel, peer-reviewed T1D research.
Description
This opportunity funds research focused on a pioneering approach to treating Type 1 Diabetes (T1D) by directly reprogramming pancreatic ductal cells into insulin-producing cells. The project leverages AI-designed mini-proteins, known as EpiBinders, to precisely activate genes necessary for this cellular transformation. By introducing these proteins and specialized genetic tools into the pancreas, the goal is to restore natural insulin production in people with T1D, potentially reducing reliance on insulin injections and enabling new strategies for cellular regeneration in diabetes and beyond.
